Evgen Pharma PLC Presentation at World Orphan Drug Congress USA (8227L)
24 Aprile 2018 - 8:00AM
UK Regulatory
TIDMEVG
RNS Number : 8227L
Evgen Pharma PLC
24 April 2018
For immediate release 24 April 2018
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Presentation at World Orphan Drug Congress USA
Evgen Pharma (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, is pleased to announce that Steve Franklin, the
Company's CEO, will present at the World Orphan Drug Congress USA
2018 in Maryland, Washington DC, on 26 April 2018.
The presentation, which is part of the Pitch & Partner track
of the congress, will focus on SFX-01, the Company's lead product,
in the treatment of subarachnoid haemorrhage ("SAH"). SFX-01 is
currently in a Phase II clinical trial in SAH, which remains on
track to report around the end of 2018.
The presentation will also refer to the ongoing Phase II trial
of SFX-01 in metastatic breast cancer, which is on track to report
an interim read-out in Q2 this year with the final read-out around
the year end.
The World Orphan Drug Congress USA 2018, which will take place
on 25-27 April 2018, focuses on all aspects of orphan drug
development and rare disease research. Further details are
available at the congress website:
http://www.terrapinn.com/conference/world-orphan-drug-congress-usa/index.stm.
This will be the second international forum that Steve Franklin
has been invited to address this month, having just returned from a
closed meeting in Madrid where he presented the "SFX-01 for
Subarachnoid Haemorrhage" clinical programme to senior scientists
from pharmaceutical companies and academia, all with a common
interest in the Nrf-2 pathway.
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466 5000
Dr Stephen Franklin, CEO
Richard Moulson, CFO
www.evgen.com
Buchanan
Mark Court, Sophie Wills, Stephanie Watson +44 (0) 20 7466 5000
Northland Capital Partners Limited
Matthew Johnson, Tom Price, Gerry Beaney
(Corporate Finance)
John Howes, Rob Rees (Corporate Broking) +44 (0) 20 3861 6625
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. The Company's core technology is Sulforadex(R), a
method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSEEFLDFASEFL
(END) Dow Jones Newswires
April 24, 2018 02:00 ET (06:00 GMT)
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Ott 2023 a Ott 2024